PAUL D. HOEPRICH, M.D.
Needed information on the use of ketoconazole in treating several kinds of systemic mycoses that do not involve the central nervous system is provided by Dismukes and associates in this issue (1). The authors' assessments of the toxicity of ketoconazole are valuable because they were derived from the careful observation of 52 patients.
There are problems, however, with the authors' evaluation of the clinical responses to ketoconazole therapy. These extend beyond the two limitations on judgment of efficacy that they noted—namely, permitting escalation of the dose and setting no requirement for either a maximum or a minimum total duration of
HOEPRICH PD. Ketoconazole in Systemic Mycoses. Ann Intern Med. ;98:105. doi: 10.7326/0003-4819-98-1-105_1
Download citation file:
Published: Ann Intern Med. 1983;98(1):105.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use